Loading...

We've got a brand new version of Simply Wall St! Try it out

Core One Labs

CNSX:COOL
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
COOL
CNSX
CA$19M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Core One Labs Inc. engages in the manufacture and sale of cannabis-infused strips in Canada and the United States. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Core One Labs has significant price volatility in the past 3 months.
COOL Share Price and Events
7 Day Returns
-33.6%
CNSX:COOL
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-68.9%
CNSX:COOL
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
COOL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Core One Labs (COOL) -33.6% -13.5% -62.6% -68.9% -63.6% -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • COOL underperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • COOL underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
COOL
Industry
5yr Volatility vs Market

Value

 Is Core One Labs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Core One Labs. This is due to cash flow or dividend data being unavailable. The share price is CA$0.83.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Core One Labs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Core One Labs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:COOL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.47
CNSX:COOL Share Price ** CNSX (2019-09-19) in CAD CA$0.83
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Core One Labs.

CNSX:COOL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:COOL Share Price ÷ EPS (both in CAD)

= 0.83 ÷ -0.47

-1.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Core One Labs is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Core One Labs is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Core One Labs's expected growth come at a high price?
Raw Data
CNSX:COOL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Core One Labs, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Core One Labs's assets?
Raw Data
CNSX:COOL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.99
CNSX:COOL Share Price * CNSX (2019-09-19) in CAD CA$0.83
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:COOL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:COOL Share Price ÷ Book Value per Share (both in CAD)

= 0.83 ÷ 0.99

0.84x

* Primary Listing of Core One Labs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Core One Labs is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Core One Labs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Core One Labs has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Core One Labs expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Core One Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Core One Labs expected to grow at an attractive rate?
  • Unable to compare Core One Labs's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Core One Labs's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Core One Labs's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:COOL Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:COOL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:COOL Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 8 -10 -10
2019-03-31 7 -8 -9
2018-12-31 4 -10 -12
2018-09-30 0 -11 -15
2018-06-30 0 -8 -16
2018-03-31 0 -7 -14
2017-12-31 0 -5 -13
2017-09-30 1 -4 -8
2017-06-30 1 -3 -4
2017-03-31 0 -2 -3
2016-12-31 0 -1 -3
2016-09-30 0 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Core One Labs is high growth as no earnings estimate data is available.
  • Unable to determine if Core One Labs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:COOL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Core One Labs Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:COOL Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.47
2019-03-31 -0.45
2018-12-31 -0.66
2018-09-30 -0.86
2018-06-30 -1.00
2018-03-31 -1.02
2017-12-31 -1.10
2017-09-30 -0.79
2017-06-30 -0.49
2017-03-31 -0.51
2016-12-31 -0.54
2016-09-30 -0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Core One Labs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Core One Labs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Core One Labs's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Core One Labs's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Core One Labs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Core One Labs has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Core One Labs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Core One Labs's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Core One Labs does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Core One Labs's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Core One Labs's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Core One Labs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Core One Labs Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:COOL Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 7.54 -9.64 10.09 0.09
2019-03-31 6.80 -8.82 9.40 0.63
2018-12-31 4.08 -12.29 8.79 1.12
2018-09-30 0.29 -14.83 12.30 2.93
2018-06-30 -0.31 -15.83 12.37 3.56
2018-03-31 0.01 -13.97 10.69 3.10
2017-12-31 0.19 -12.60 9.76 2.71
2017-09-30 0.85 -7.51 5.53 1.12
2017-06-30 0.85 -3.65 2.43 0.34
2017-03-31 0.22 -3.13 1.95 0.21
2016-12-31 0.06 -2.87 1.65 0.07
2016-09-30 0.01 -1.82 1.54 0.06
2016-06-30 0.05 -1.44 1.20 0.04
2016-03-31 0.07 -1.43 1.11 0.06
2015-12-31 0.06 -1.21 0.86 0.06
2015-09-30 0.07 -1.01 0.64 0.05
2015-06-30 0.03 -0.80 0.48 0.04
2015-03-31 -0.49 0.29
2014-12-31 -0.43 0.30
2014-09-30 -0.29 0.29
2014-06-30 -0.26 0.28
2014-03-31 -0.43 0.29
2013-12-31 -0.44 0.31
2013-09-30 -0.44 0.26
2013-06-30 -0.43 0.25
2013-03-31 -0.31 0.29
2012-12-31 -0.46 0.44
2012-09-30 -0.40 0.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Core One Labs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Core One Labs has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Core One Labs improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Core One Labs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Core One Labs has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Core One Labs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Core One Labs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Core One Labs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Core One Labs has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Core One Labs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Core One Labs has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Core One Labs Company Filings, last reported 2 months ago.

CNSX:COOL Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 21.47 0.00 4.92
2019-03-31 18.75 0.77 5.38
2018-12-31 16.28 0.72 0.99
2018-09-30 19.91 0.00 1.26
2018-06-30 22.12 0.00 5.97
2018-03-31 14.50 0.73 1.33
2017-12-31 10.89 0.66 2.75
2017-09-30 11.09 0.00 1.78
2017-06-30 10.43 0.09 6.12
2017-03-31 1.82 0.09 0.14
2016-12-31 1.42 0.00 0.44
2016-09-30 1.54 0.11 0.84
2016-06-30 0.45 0.04 0.01
2016-03-31 0.65 0.00 0.00
2015-12-31 1.06 0.00 0.12
2015-09-30 1.65 0.00 0.14
2015-06-30 1.96 0.00 0.25
2015-03-31 -0.10 0.11 0.20
2014-12-31 -0.01 0.10 0.20
2014-09-30 -0.04 0.43 0.53
2014-06-30 0.07 0.41 0.54
2014-03-31 0.01 0.00 0.03
2013-12-31 0.07 0.00 0.06
2013-09-30 0.14 0.00 0.18
2013-06-30 0.22 0.00 0.26
2013-03-31 0.44 0.00 0.35
2012-12-31 0.51 0.00 0.36
2012-09-30 0.58 0.00 0.43
  • Core One Labs has no debt.
  • Core One Labs has no debt compared to 5 years ago when it was 569.8%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Core One Labs has less than a year of cash runway based on current free cash flow.
  • Core One Labs has less than a year of cash runway if free cash flow continues to grow at historical rates of 55.2% each year.
X
Financial health checks
We assess Core One Labs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Core One Labs has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Core One Labs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Core One Labs dividends.
If you bought CA$2,000 of Core One Labs shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Core One Labs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Core One Labs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:COOL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Core One Labs has not reported any payouts.
  • Unable to verify if Core One Labs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Core One Labs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Core One Labs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Core One Labs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Core One Labs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Core One Labs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Core One Labs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brad Eckenweiler
COMPENSATION CA$731,334
AGE 65
TENURE AS CEO 4.3 years
CEO Bio

Mr. Brad Paul Eckenweiler has been Chief Executive Officer of Lifestyle Delivery Systems Inc since May 22, 2015.Mr. Eckenweiler has been Director of Lifestyle Delivery Systems Inc since May 1, 2015. Mr. Eckenweiler served as the Chief Executive Officer of Triton Emission Solutions Inc. from September 9, 2013 to May 2014. He served as the Chief Executive Officer of Caanna. He has been a Director of Lifestyle Delivery Systems Inc. since May 1, 2015. Mr. Eckenweiler served as a Director of Triton Emission Solutions Inc. from September 3, 2013 to May 2014. He served as a Director of Caanna.

CEO Compensation
  • Brad's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Brad's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Core One Labs management team in years:

3.6
Average Tenure
65
Average Age
  • The tenure for the Core One Labs management team is about average.
Management Team

Brad Eckenweiler

TITLE
CEO & Director
COMPENSATION
CA$731K
AGE
65
TENURE
4.3 yrs

Yana Silina

TITLE
CFO, Corporate Secretary & Director
COMPENSATION
CA$116K
AGE
41
TENURE
3.8 yrs

John Sanderson

TITLE
Chief Science Officer & Director
COMPENSATION
CA$79K
AGE
69
TENURE
3.4 yrs

Casey Fenwick

TITLE
President & Director
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Core One Labs board of directors in years:

1.7
Average Tenure
65
Average Age
  • The average tenure for the Core One Labs board of directors is less than 3 years, this suggests a new board.
Board of Directors

Brad Eckenweiler

TITLE
CEO & Director
COMPENSATION
CA$731K
AGE
65
TENURE
4.3 yrs

Yana Silina

TITLE
CFO, Corporate Secretary & Director
COMPENSATION
CA$116K
AGE
41
TENURE
1.7 yrs

John Sanderson

TITLE
Chief Science Officer & Director
COMPENSATION
CA$79K
AGE
69
TENURE
1.7 yrs

Casey Fenwick

TITLE
President & Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
09. Feb 19 Sell Arni Johannson Individual 04. Feb 19 07. Feb 19 -15,000 CA$2.97 CA$-42,093
X
Management checks
We assess Core One Labs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Core One Labs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Core One Labs Inc. engages in the manufacture and sale of cannabis-infused strips in Canada and the United States. It also licenses its technology to produce infused strips for inclusion of a range of ingredients, including over the counter medications, homeopathic, nutraceutical, vitamins, and supplements. The company offers cannabis products, including CannaStrips, which are cannabis-infused strips; and oils, distillates, and resin under the Rêveur brand. It also provides Track and Trace software, as well as cannabis processing services, including supply chain management, lab testing, and extraction services. In addition, the company offers consulting services for cultivation, extraction, and manufacturing, as well as financing, transportation, nursery, and cultivation services; and holds real estate properties and equipment. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was founded in 2010 and is headquartered in Vancouver, Canada.

Details
Name: Core One Labs Inc.
COOL
Exchange: CNSX
Founded: 2010
CA$19,292,676
23,244,189
Website: http://www.lifestyledeliverysystems.com
Address: Core One Labs Inc.
1130 West Pender Street,
Suite 820,
Vancouver,
British Columbia, V6E 4A4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX COOL Common Shares Canadian National Stock Exchange CA CAD 24. Jan 2014
DB LD61 Common Shares Deutsche Boerse AG DE EUR 24. Jan 2014
Number of employees
Current staff
Staff numbers
0
Core One Labs employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:13
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.